In this episode, we review recommendations 45 to 50 from the 2025 American Thyroid Association guidelines on long term management of differentiated thyroid cancer. Key topics include:

• Individualization of TSH suppression strategy

• Long term considerations for TSH suppression in low and intermediate risk patients

• Monitoring serum thyroglobulin and Tg antibodies as markers of disease status

• Follow up protocols for low risk differentiated thyroid cancer, including when to discontinue ultrasound and biochemical monitoring

• The role of radioiodine whole body scintigraphy in follow up care

•Indications for advanced imaging with fluorodeoxyglucose PET/CT in high risk patients